EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 35 (Novembre 2019) Hors série n° 2 Med Sci (Paris), 35 (2019) 18-23 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 35, Novembre 2019
Les Cahiers de Myologie
Page(s) 18 - 23
Section Mise au point
DOI https://doi.org/10.1051/medsci/2019178
Publié en ligne 20 décembre 2019
  1. Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep 2018; 20: 28. [CrossRef] [PubMed] [Google Scholar]
  2. Tansley SL, Simou S, Shaddick G, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 2017; 84: 55–64. [CrossRef] [PubMed] [Google Scholar]
  3. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheum (Hoboken, NJ) 2017; 69: 2271–82. [Google Scholar]
  4. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14: 337–45. [CrossRef] [PubMed] [Google Scholar]
  5. Mariampillai K, Granger B, Amelin D, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 2018; 75: 1528–37. [Google Scholar]
  6. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–7. [Google Scholar]
  7. Reichlin M, Mattioli M. Description of a serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 1976; 5: 12–20. [PubMed] [Google Scholar]
  8. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360–74. [CrossRef] [PubMed] [Google Scholar]
  9. Damoiseaux J, Vulsteke JB, Tseng CW, et al. Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev 2019; 18: 293–305. [Google Scholar]
  10. Hengstman GJD, Vree Egberts WTM, Seelig HP, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65: 242–5. [CrossRef] [PubMed] [Google Scholar]
  11. Landon-Cardinal O, Monseau G, Schoindre Y, et al. Anti-Mi2 dermatomyositis revisited: pure DM phenotype with muscle fiber necrosis and high risk of malignancy [abstract]. Arthritis . Rheumatol 2016; 68 (Suppl 10). Accessed July 20, 2017. [Google Scholar]
  12. Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, et al. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 2015; 42: 1448–54. [CrossRef] [PubMed] [Google Scholar]
  13. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682–9. [CrossRef] [PubMed] [Google Scholar]
  14. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513–22. [CrossRef] [PubMed] [Google Scholar]
  15. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 2015; 72: 449–55. [CrossRef] [PubMed] [Google Scholar]
  16. Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523–32. [CrossRef] [PubMed] [Google Scholar]
  17. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65: 2954–62. [CrossRef] [PubMed] [Google Scholar]
  18. Aussy A, Fréret M, Gallay L, et al. The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. Arthritis Rheumatol (Hoboken NJ) 2019; 71: 1360–70. [CrossRef] [Google Scholar]
  19. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol 2018; 14: 290–302. [CrossRef] [PubMed] [Google Scholar]
  20. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47: 324–8. [CrossRef] [PubMed] [Google Scholar]
  21. Orandi AB, Dharnidharka VR, Al-Hammadi N, et al. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J 2018; 16: 84. [Google Scholar]
  22. Yasin SA, Schutz PW, Deakin CT, et al. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol 2019; 45: 495–512. [CrossRef] [PubMed] [Google Scholar]
  23. Aouizerate J, De Antonio M, Bader-Meunier B, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology (Oxford) 2018; 57: 873–9. [CrossRef] [PubMed] [Google Scholar]
  24. Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 2017; 69: 1771–6. [CrossRef] [PubMed] [Google Scholar]
  25. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571–6. [CrossRef] [PubMed] [Google Scholar]
  26. Hall JC, Casciola-Rosen L, Samedy LA, et al. anti-Mda5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65: 1307–15. [CrossRef] [PubMed] [Google Scholar]
  27. Allenbach Y, Leroux G, Suárez-Calvet X, et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 2016; 186: 691–700. [CrossRef] [PubMed] [Google Scholar]
  28. Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68: 689–94. [CrossRef] [PubMed] [Google Scholar]
  29. Betteridge Z, Gunawardena H, North J, et al. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56: 3132–7. [CrossRef] [PubMed] [Google Scholar]
  30. Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep [Internet]. 15 mars 2017 [cité 2 juin 2019]; 7. Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428032/. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.